SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment o… Read more
Market Cap & Net Worth: SQZ Biotechnologies Company (SQZB)
SQZ Biotechnologies Company (PINK:SQZB) has a market capitalization of $825.75K ($825.75K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #36814 globally and #11980 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SQZ Biotechnologies Company's stock price $0.03 by its total outstanding shares 29491125 (29.49 Million).
SQZ Biotechnologies Company Market Cap History: 2020 to 2025
SQZ Biotechnologies Company's market capitalization history from 2020 to 2025. Data shows change from $854.65 Million to $825.75K (-75.10% CAGR).
SQZ Biotechnologies Company Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SQZ Biotechnologies Company's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
SQZ Biotechnologies Company's market cap is 0.05 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $854.65 Million | $21.00 Million | -$50.52 Million | 40.70x | N/A |
| 2021 | $263.36 Million | $27.10 Million | -$68.74 Million | 9.72x | N/A |
| 2022 | $21.82 Million | $21.03 Million | -$79.46 Million | 1.04x | N/A |
| 2023 | $589.82K | $12.20 Million | -$71.64 Million | 0.05x | N/A |
Competitor Companies of SQZB by Market Capitalization
Companies near SQZ Biotechnologies Company in the global market cap rankings as of March 19, 2026.
Key companies related to SQZ Biotechnologies Company by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
SQZ Biotechnologies Company Historical Marketcap From 2020 to 2025
Between 2020 and today, SQZ Biotechnologies Company's market cap moved from $854.65 Million to $ 825.75K, with a yearly change of -75.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $825.75K | 0.00% |
| 2024 | $825.75K | +40.00% |
| 2023 | $589.82K | -97.30% |
| 2022 | $21.82 Million | -91.71% |
| 2021 | $263.36 Million | -69.19% |
| 2020 | $854.65 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of SQZ Biotechnologies Company was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $825.75K USD |
| MoneyControl | $825.75K USD |
| MarketWatch | $825.75K USD |
| marketcap.company | $825.75K USD |
| Reuters | $825.75K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.